Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Telix Pharmaceuticals ( (AU:TLX) ) is now available.
Challenger Limited has announced that it has ceased to be a substantial holder in Telix Pharmaceuticals Ltd. This change in holding status is significant as it indicates a shift in Challenger’s investment strategy or portfolio composition, potentially impacting Telix’s shareholder structure and market perception.
The most recent analyst rating on (AU:TLX) stock is a Hold with a A$16.50 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
YTD Price Performance: -40.67%
Average Trading Volume: 2,161,123
Technical Sentiment Signal: Sell
Current Market Cap: A$4.94B
For a thorough assessment of TLX stock, go to TipRanks’ Stock Analysis page.